Hospital Cuf Descobertas S.A. — Clinical Trial Site

76 Registered trials

28 Currently recruiting

Organisation

Hospital Cuf Descobertas S.A.

Location

Lisbon, Portugal

Identifier

ORG-100041451

Address

Rua Mario Botas 1, 1998-018, Portugal

Departments

-
#2104: Servico Imunoalergologia
2704; Serviço de Dermatologia
3302: Serviço de Dermatologia
351002: Oncologia Medica
5002:Serviço de Hemato-Oncologia
9230: Serviço de Dermatologia
Allergology
Cardiologia
Cardiology Department
Centro de Alergia
Centro de Dermatologia
Dermatologia
Dermatology
Dermatology Department
Hemato-Oncologia
Medical Oncology
N/A
na
Neurology
Oftalmologia
Oncologia
Oncology
Oncology Department
Paediatrics
Pediatria
Pulmonology department
Rheumatology
Serviço de Dermatologia
Serviço de Hemato-oncologia
Serviço de Nefrologia
Serviço de Oncologia
Serviço de Oncologia Médica
Serviço de Pediatria

Clinical trials at this site (76)

Search interface

A study to evaluate the efficacy and safety of QMF149 (indacaterol acetate/mometasone furoate) versus Budesonide in children from 6 to less … Recruiting

2022-501899-26-00 Asthma 5 2023-09-01
A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting

2022-502917-27-00 Migraine 5 2023-03-07
A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Recruiting

2023-505634-94-00 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneo 10 2023-02-02
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten (CK-3773274) in Adults With Hypertrophic Cardiomyo… Recruiting

2023-508963-58-00 Symptomatic hypertrophic cardiomyopathy (HCM) 4 2022-01-31
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes… Recruiting

2024-511246-39-00 Solid tumours with HER2 aberrations 1 2021-07-27
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Recruiting

2023-508956-20-00 Hidradenitis suppurativa 5 2020-03-12
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513282-39-00 Hidradenitis Suppurativa (HS) 5 2025-05-28
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended

2024-516609-22-00 Primary Sjögren’s Disease 5 2025-04-15
A research study to look into the long-term effect on weight loss of CagriSema in people with obesity Ended

2024-512144-39-00 Obesity 5 2025-01-22
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis Ended

2024-510753-10-00 Prurigo Nodularis 5 2024-11-01
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
Efficacy and safety of oral minoxidil in women with hormone-imbalanced hair loss Ended

2023-503383-17-01 Female androgenetic alopecia 5 2024-10-10
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended

2023-505061-82-01 Alopecia Areata 5 2024-06-17
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy… Ended

2023-503669-50-00 Moderate-to-Severe Thyroid Eye Disease 5 2023-12-27
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
A Clinical Study of Lazertinib with Subcutaneous Amivantamab Compared with Intravenous Amivantamab in Patients with EGFR-mutated Advanced or… Ended

2024-512045-16-00 EGFR-mutated Advanced or Metastatic Non-small Cell Lung 5 2022-08-18
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01